Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

166.80 -18.70 (-10.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024 ↗
NBIX stock results show that Neurocrine Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win ↗
The company makes Ingrezza, a treatment for the movement disorder known as tardive dyskinesia. 
Via Investor's Business Daily
News headline image
Sarepta Therapeutics Stock Shows Improved Technical Strength ↗
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73. 
Via Investor's Business Daily
News headline image
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review ↗
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
Why NASDAQ:NBIX Is a Standout High-Growth Stock in a Consolidation Phase. ↗
Via Chartmill
News headline image
Where Neurocrine Biosciences Stands With Analysts ↗
 
Via Benzinga
News headline image
3 Red-Hot Biotech Rockets Blasting Off in 2024 ↗
The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits. 
Via InvestorPlace
Topics Economy
News headline image
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder ↗
Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in... 
Via Benzinga
News headline image
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win ↗
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza. 
Via Investor's Business Daily
News headline image
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
From Sentia Medical Sciences, Inc.
Via GlobeNewswire
News headline image
The 5 Stocks Most Sold By Insiders This Year
Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices. 
Via MarketBeat
News headline image
NASDAQ:NBIX is not too expensive for the growth it is showing. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is showing decent growth, but is still valued reasonably. 
Via Chartmill
News headline image
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout. ↗
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
News headline image
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. ↗
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. 
Via Chartmill
News headline image
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag. ↗
In a market where value is scarce, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind ↗
DexCom, Blackstone and Royal Caribbean head this list of five stocks. 
Via Investor's Business Daily
Topics Economy Stocks
News headline image
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform ↗
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term... 
Via Benzinga
News headline image
Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago. 
Via Investor's Business Daily
News headline image
Why Quality-Oriented Investors Should Consider NASDAQ:NBIX. ↗
Analyzing the Quality Characteristics of NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
News headline image
Decoding 8 Analyst Evaluations For Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
Is NASDAQ:NBIX on the Verge of a Major Breakout as a Strong Growth Stock? ↗
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
News headline image
AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base ↗
Three of the featured stocks are closing in on record highs. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
NASDAQ:NBIX is probably undervalued for the fundamentals it is displaying. ↗
When you look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences ↗
 
Via Benzinga
News headline image
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success ↗
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector. 
Via InvestorPlace
News headline image
Amicus Therapeutics Stock Sees RS Rating Improve To 74 ↗
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday. 
Via Investor's Business Daily
News headline image
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. ↗
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering. 
Via Chartmill
News headline image
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat ↗
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. 
Via Investor's Business Daily
News headline image
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark ↗
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84. 
Via Investor's Business Daily
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.